Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease?

Current Vascular Pharmacology

Volumn 10, Issue 4, 2012, Pages 432-441

  Burillo, Elena ^a   Martín Fuentes, Paula ^a   Mateo Gallego, Rocío ^a   Baila Rueda, Lucía ^a   Cenarro, Ana ^a   Ros, Emilio ^b,c   Civeira, Fernando ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Eicosapentaenoic acid and docosahexaenoic acid; High density lipoprotein; Omega 3 PUFAs

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ATORVASTATIN; DOCOSAHEXAENOIC ACID; FISH OIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SUPPLEMENTATION; THROMBOSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861676215     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112800812845     Document Type: Review

References (109)

1. Calder PC. n-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (London) 2004; 107: 1-11.
2. Harris WS. Extending the cardiovascular benefits of omega-3 fatty acids. Curr Atheroscler Rep 2005; 7: 375-80.
3. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011; 364: 2439-50.
4. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65 (Suppl): 1645-54.
5. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manag 2006; 2: 251-62.
6. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19-30.
7. Mori TA, Woodman RJ. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006; 9: 95-104.
8. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006; 98 (Suppl): 71i-76i.
9. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil A. Metaanalysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007; 50: 1593-602.
10. Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009; 136: 4-16.
11. Musa-Veloso K, Binns MA, Kocenas AC, et al. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev 2010; 68: 155-67.
12. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363-79.
13. Griffin BA. The effect of n-3 fatty acids on low density lipoprotein subfractions. Lipids 2001; 36 (Suppl): 91-97.
14. Cazzola R, Russo-Volpe S, Miles EA, et al. Age-and dosedependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 2007; 193: 159-67.
15. Skulas-Ray AC, Kris-Etherton PM, Harris WS, Van den Heuvel JP, Wagner PR, West SG. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011; 93: 243-52.
16. Egert S, Kannenberg F, Somoza V, Erbersdobler HF, Wahrburg U. Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 2009, 139: 861-8.
17. Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Effects of prescription omega-3-acid ethyl esters on non-highdensity lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 2010, 85: 122-8.
18. Maki KC, Lawless AL, Kelley KM, et al. Effects of prescription omega-3-Acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol 2011, 57: 489-94.
19. Okuda N, Ueshima H, Okayama A, et al.; for the INTERLIPID Research Group. Relation of long chain n-3 polyunsaturated fatty acid intake to serum high density lipoprotein cholesterol among Japanese men in Japan and Japanese-American men in Hawaii: the INTERLIPID study. Atherosclerosis 2005; 178: 371-9.
20. Makhoul Z, Kristal AR, Gulati R, et al. Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. Am J Clin Nutr 2010; 91: 777-85.
21. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009; 50: S195-S200.
22. Francis GA. The complexity of HDL. Biochim Biophys Acta 2010; 1801: 1286-93.
23. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54: 788-800.
24. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57: 392-410.
25. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011; 22: 176-85.
26. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010; 30: 139-43.
27. Abbey M, Clifton P, Kestin M, Belling B, Nestel P. Effect of fish oil on lipoproteins, lecithin:cholesterol acyltransferase, and lipid transfer protein activity in humans. Arteriosclerosis 1990; 10: 85-94.
28. Suzukawa M, Abbey M, Howe PRC, Nestel PJ. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 1995; 36: 473-84.
29. Grimsgaard S, Bonaa KH, Hansen JB, Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997; 66: 649-59.
30. Dunstan DW, Mori TA, Puddey IB, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. Diabetes Care 1997; 20: 913-21.
31. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085-94.
32. Frénais R, Ouguerram K, Maugeais C, et al. Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis 2001; 157: 131-5.
33. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002; 76: 1007-15.
34. Tholstrup T, Hellgren LI, Petersen M, et al. A solid dietary fat containing fish oil redistributes lipoprotein subclasses without increasing oxidative stress in men. J Nutr 2004; 134: 1051-7.
35. Buckley R, Shewring B, Turner R, Yaqoob P, Minihane AM. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 2004; 92: 477-83.
36. Wilkinson P, Leach C, Ah-Sing EE, et al. Influence of linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 2005; 181: 115-24.
37. Maki KC, Van Elswyk ME, McCarthy D, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr 2005; 24: 189-99.
38. Griffin MD, Sanders TAB, Davies IG, et al. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP Study. Am J Clin Nutr 2006; 84: 1290-8.
39. Chan DC, Watts GF, Nguyen MN, Barrett PH. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr 2006; 84: 37-43.
40. Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 2007; 86: 324-33.
41. Caslake MJ, Miles EA, Kofler BM, et al. Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr 2008; 88: 618-29.
42. Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoproteinassociated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol 2009; 3: 332-40.
43. Wooten JS, Biggerstaff KD, Ben-Ezra V. Responses of LDL and HDL particle size and distribution to omega-3 fatty acid supplementation and aerobic exercise. J Appl Physiol 2009; 107: 794-800.
44. Lindqvist HM, Langkilde AM, Undeland I, Sandberg AS. Herring (Clupea harengus) intake influences lipoproteins but not inflammatory and oxidation markers in overweight men. Br J Nutr 2009; 101: 383-90.
45. Maki KC, Lawless AL, Kelley KM, et al. Effects of prescription omega-3-Acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol 2011; 57: 489-94.
46. Neff LM, Culiner J, Cunningham-Rundles S, et al. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr 2011; 141: 207-13.
47. Harris WS, Poston W, Haddock CK. Tissue n3 and n6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007; 193: 1-10.
48. Harris WS. The omega-3 index: from biomarker to risk marker to risk factor. Curr Atheroscler Rep 2009; 11: 411-7.
49. Deckelbaum RJ, Worgall TS, Seo T. n-3 Fatty acids and gene expression. Am J Clin Nutr 2006; 83 (Suppl): 1520-5.
50. Brinton EA, Eisenberg S, Breslow JL. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest 1990; 85: 144-51.
51. Harris WS, Lu G, Rambjør GS, et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 1997; 66: 254-60.
52. Pownall HJ, Brauchi D, Kilinç C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999; 143: 285-97.
53. Yusuf S, Hawken S, Ounpuu S, et al.; INTERHEART Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
54. Pan M, Cederbaum AI, Zhang Y-L, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004; 113: 1277-87.
55. Mineo C, Deguchi H, Griffin J, Shaul P. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-64.
56. Barter P, Nicholls S, Rye K, Anantharamaiah G, Navab M, Fogelman A. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-72.
57. Navab M, Hama S, Cooke C, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-94.
58. Navab M, Hama S, Anantharamaiah G, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-508.
59. Vaisar T, Pennathur S, Green P, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
60. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
61. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-8.
62. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 2010; 21: 781-92.
63. Torrejon C, Jung UJ, Deckelbaum RJ. n-3 Fatty acids and cardiovascular disease: actions and molecular mechanisms. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 319-26.
64. Rees D, Miles EA, Banerjee T, et al. Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 2006; 83: 331-42.
65. Serhan CN, Clish CB, Brannon J, Colgan SP, Gronert K, Chiang N. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. J Physiol Pharmacol 2000; 51: 643-54.
66. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-non-steroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000; 192: 1197-204.
67. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-61.
68. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101: 8491-6.
69. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 2002; 277: 8755-8.
70. Endres S, Meydani SN, Ghorbani R, Schindler R, Dinarello CA. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol 1993; 54: 599-603.
71. Lee JY, Plakidas A, Lee WH, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003; 44: 479-86.
72. Burillo E, Mateo-Gallego R, Cenarro A, et al. Beneficial effects of omega-3 fatty acids in the proteome of HDL. 2011 (Submitted)
73. de Roos B, Geelen A, Ross K, et al. Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers. Proteomics 2008; 8: 1965-74.
74. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem 1998; 273: 6080-7.
75. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273: 6088-95.
76. Navab M, Berliner J, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-8.
77. Lorenz R, Spengler U, Fischer S, Duhm J, Weber PC. Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. Circulation 1983; 67: 504-11.
78. Archer SL, Green D, Chamberlain M, Dyer AR, Liu K. Association of dietary fish and n-3 fatty acid intake with hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Arterioscler Thromb Vasc Biol 1998; 18: 1119-23.
79. Mori TA, Beilin LJ, Burke V, Morris J, Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 279-86.
80. Phang M, Garg ML, Sinclair AJ. Inhibition of platelet aggregation by omega-3 polyunsaturated fatty acids is gender specificredefining platelet response to fish oils. Prostaglandins Leukot Essent Fatty Acids 2009; 81: 35-40.
81. Barcelli U, Glas-Greenwalt P, Pollak VE. Enhancing effect of dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res 1985; 39: 307-12.
82. Montegaard C, Tulk HM, Lauritzen L, Tholstrup T, Robinson LE. Acute ingestion of long-chain (n-3) polyunsaturated fatty acids decreases fibrinolysis in men with metabolic syndrome. J Nutr 2010; 140: 38-43.
83. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute plateletdependent thrombus formation. Am J Cardiol 1999; 84: 1011-7.
84. Oravec S, Demuth K, Myara I, Hornych A. The effect of high density lipoprotein subfractions on endothelial eicosanoid secretion. Thromb Res 1998; 92: 65-71.
85. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88: 998-1003.
86. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109: IV6-19.
87. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. Testing and clinical relevance. Circulation 2007; 115: 1285-95.
88. Israel DH, Gorlin R. Fish oils in the prevention of atherosclerosis. J Am Coll Cardiol 1992; 19: 174-85.
89. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000; 71 (Suppl 1): 213S-223S.
90. Cottin SC, Sanders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011; 70: 215-31.
91. Cockerill G, Rye K, Gamble J, Vadas M, Barter P. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987-94.
92. Tölle M, Pawlak A, Schuchardt M, et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28: 1542-8.
93. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8: 222-32.
94. Bonilla DL, Ly LH, Fan YY, Chapkin RS, McMurray DN. Incorporation of a dietary omega 3 fatty acid impairs murine macrophage responses to Mycobacterium tuberculosis. PLoS One 2010; 5: e10878.
95. Mineo C, Shaul PW. Role of high-density lipoprotein and scavenger receptor B type in the promotion of endothelial repair. Trends Cardiovasc Med 2007; 17: 156-61.
96. Pérez-Ruiz A, Montes R, Velasco F, et al. Regulation by nitric oxide of endotoxin-induced tissue factor and plasminogen activator inhibitor-1 in endothelial cells. Thromb Haemost 2002; 88: 1060-5.
97. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000; 101: 2144-8.
98. Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003; 107: 2337-41.
99. Ou J, Wang J, Xu H, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res 2005; 97: 1190-7.
100. deGoma E, de Goma R, Rader D. Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51: 2199-211.
101. Kuvin JT, Rämet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144: 165-72.
102. Michel JB, Virmani R, Arbustini E, Pasterkamp G. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 2011; 32: 1977-85.
103. Sudheendran S, Chang CC, Deckelbaum RJ. N-3 vs. saturated fatty acids: effects on the arterial wall. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 205-9.
104. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-61.
105. No authors listed. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354: 447-55.
106. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130: 554-62.
107. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003; 361: 477-85.
108. Bell JD, Barnard ML, Parkes HG, et al. Effects of n-3 fatty acids on the NMR profile of plasma lipoproteins. J Lipid Res 1996; 37: 1664-74.
109. Feller SE. Acyl chain conformations in phospholipid bilayers: a comparative study of docosahexaenoic acid and saturated fatty acids. Chem Phys Lipids 2008; 153: 76-80.